Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

NCT06886009 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-03-31

No results posted yet for this study

Summary

The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.

Conditions

  • Generalized Pustular Psoriasis

Interventions

DRUG

Spevigo®

Intravenous

Sponsors & Collaborators

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2029-06-08
Completion
2029-06-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886009 on ClinicalTrials.gov